April 29, 2025 -
Toronto, Canada – April 29, 2025 – MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, and DocNow, an innovative post-acute Electronic Health Record (EHR) platform, today announced their integration for the MolecuLightDX™ device.
This powerful collaboration will
… Read MoreApril 8, 2025 -
Toronto, Canada – April 8th, 2025 – MolecuLight, a global pioneer in point-of-care fluorescence imaging for rapid bacterial detection in wounds, announces its presence at the American Burn Association (ABA) Annual Meeting in Phoenix, AZ, April 8-11. MolecuLight will showcase its innovative fluorescence imaging systems that empower
… Read MoreApril 3, 2025 -
Toronto, Canada – April 3rd, 2025 – A groundbreaking study published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders has unveiled a significant relationship between bacterial load and pain in patients with venous leg ulcers (VLUs), showcasing the potential of MolecuLight’s fluorescence imaging technology to
… Read MoreFebruary 28, 2025 -
Pittsburgh, PA – 2/28/2025 – MolecuLight Inc., the leader in point-of-care fluorescence imaging devices for wound care, is excited to announce its participation in the 2025 Cellular, Acellular, and Matrix-like Products (CAMPs) Wound Care Summit, held from February 28th to March 2nd in Fort Lauderdale, Florida. In
… Read MoreJanuary 28, 2025 -
Toronto, CANADA – January 28th, 2025 – MolecuLight Corp., a leader in point-of-care fluorescence imaging for wound care, is excited to announce that Dr. Michael N. Desvigne, a renowned board-certified plastic surgeon and wound care clinician, will present the clinical and surgical benefits of MolecuLight’s fluorescence imaging
… Read MoreJanuary 6, 2025 -Strategic financing will enable MolecuLight to further accelerate commercialization
Pittsburgh, PA January 6, 2025 – MolecuLight Inc.., a global medical device company pioneering point-of-care fluorescence imaging for measuring bacterial load in wounds, today announced it has secured a $27.5 million investment from Hayfin Capital Management LLP (“Hayfin”).
… Read MoreAugust 27, 2024 -
Pittsburgh, PA, USA – August 27th, 2024 – MolecuLight Corp., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and digital wound measurement, announced today that their flagship wound imaging device, MolecuLightDX, seamlessly integrates with the Intellicure EHR platform.
Wound Care Clinicians who
… Read MoreJune 4, 2024 -
Toronto, CANADA – June 4th, 2024 – MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, is proud to announce a groundbreaking study led by Drs. Charles Andersen and Alisha Oropallo, titled Enhancing Wound Care: The Synergistic Potential
… Read MoreMay 30, 2024 -
Toronto, CANADA – May 30th, 2024 – MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, celebrates the publication of a groundbreaking study in the prestigious Burns Journal. Titled “Bacterial Fluorescence Imaging as a Predictor
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s
Technology
Breakthrough Designation
MolecuLight
i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2026
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.